Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab

References

• Brinkmann U, Kontermann RE. Bispecific antibodies. Science (New York, NY). 2021;372:916–8. PMID: 34045345. doi:10.1126/science.abg1209.
   Google Scholar
• White I, Tamot N, Doddareddy R, Ho J, Jiao Q, Harvilla PB, Yang T-Y, Geist B, Borrok MJ, Truppo MD, et al. Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment. MAbs. 2021;13:1987180. PMID: 34693867. doi:10.1080/19420862.2021.1987180.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14:2014296. PMID: 35030985. doi:10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall’Acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep. 2017;7:40098. PMID: 28067257. doi:10.1038/srep40098.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, Hair J, Jones DC, Hasani S, Wang B, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1+ activated T cells. Cancer Discov. 2021;11:1100–17. PMID: 33419761. doi:10.1158/2159-8290.CD-20-1445.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570–74. PMID: 23023498. doi:10.1038/nm.2942.
   PubMed Web of Science ®Google Scholar
• Yada K, Nogami K. Novel insights and new developments regarding coagulation revealed by studies of the anti-factor IXa (Activated Factor IX)/factor X bispecific antibody. Emicizumab Arterioscler Thromb Vasc Biol. 2020;40:1148–54. PMID: 32237902. doi:10.1161/ATVBAHA.120.312919.
   PubMed Web of Science ®Google Scholar
• Drake A, Abdiche Y, Papalia G. 2018. Biophysical considerations for development of antibody-based therapeutics [Internet]. In Tabrizi M, Bornstein G, Klakamp S, editors. Development of antibody-based therapeutics. Singapore:Springer; cited 2022 Jul 13. p. 71–132.
   Google Scholar
• Register AC, Tarighat SS, Lee HY. Bioassay development for bispecific antibodies-challenges and opportunities. Int J Mol Sci. 2021;22:5350. PMID: 34069573. doi:10.3390/ijms22105350.
   PubMed Web of Science ®Google Scholar
• Hampel PA, Strasser R, Fischer F, Rant U. Assembly and characterization of a slingshot DNA nanostructure for the analysis of bivalent and bispecific analytes with biosensors. Langmuir. 2018;34:14796–801. PMID: 30269507. doi:10.1021/acs.langmuir.8b02124.
   PubMed Web of Science ®Google Scholar
• Daub H, Traxler L, Ismajli F, Groitl B, Itzen A, Rant U. The trimer to monomer transition of tumor necrosis factor-alpha is a dynamic process that is significantly altered by therapeutic antibodies. Sci Rep. 2020;10:9265. PMID: 32518229. doi:10.1038/s41598-020-66123-5.
   PubMed Web of Science ®Google Scholar
• Jendroszek A, Kjaergaard M. Nanoscale spatial dependence of avidity in an IgG1 antibody. Sci Rep. 2021;11:12663. PMID: 34135438. doi:10.1038/s41598-021-92280-2.
   PubMed Web of Science ®Google Scholar
• Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP, et al. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun. 2021;12:3790. PMID: 34145240. doi:10.1038/s41467-021-23948-6.
   PubMed Web of Science ®Google Scholar
• Darling RJ, Brault P-A. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev Technol. 2004;2:647–57. PMID: 15674023. doi:10.1089/adt.2004.2.647.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A, Kawabe Y, Igawa T, Tsunoda H, Nogami K, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117:1348–57. PMID: 28451690. doi:10.1160/TH17-01-0030.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs. 2015;7:377–89. PMID: 25621507. doi:10.1080/19420862.2015.1007816.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130:2463–68. PMID: 29042366. doi:10.1182/blood-2017-08-801662.
   PubMed Web of Science ®Google Scholar
• Beike H, Daub H, Fjolla I, Langer A, Rant U, Strasser R . Method for detecting and/or characterizing the interaction between proteins and small molecules. US20200132678A1. Cited 2018 June 21 Application filed.
   Google Scholar
• Schiettecatte J, Anckaert E, Smitz J. Interferences in Immuno-assays [Internet]. IntechOpen. 2012; cited 2022 Jul 13. doi:10.5772/35797.
   Google Scholar
• Ward G, Simpson A, Boscato L, Hickman PE. The investigation of interferences in immunoassay. Clin Biochem. 2017;50:1306–11. PMID: 28847718. doi:10.1016/j.clinbiochem.2017.08.015.
   PubMed Web of Science ®Google Scholar
• Shima M. Bispecific antibodies and advances in non-gene therapy options in hemophilia. Res Pract Thromb Haemost. 2020;4:446–54. PMID: 32548546. doi:10.1002/rth2.12337.
   PubMed Web of Science ®Google Scholar